ClinicalTrials.gg
CompletedNCT00089674Updated Oct 17, 2018Results posted

AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer

A Phase 3 interventional study of AMG 162 and Placebo in Prostate Cancer, sponsored by Amgen. Completed. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-17.

Sponsored by Amgen · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,468
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 10 studies testing denosumab in Prostatic Neoplasms — none open to participants now, none under way, none of them phase 3. Denosumab · Prostatic Neoplasms.

Enrollment
Largest of 10
1,468 · median 324
Started
2004
the only one that year
Phase 3
8 of 10
none open now
Registered
1st of 10
by date
Lead sponsor
7 of 10
Amgen

Among the 10 studies testing denosumab in Prostatic Neoplasms, this one has the largest enrollment, is the only one that started in 2004, is one of 8 in phase 3, and was the 1st registered.

Prostatic Neoplasms

7,053 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 10 studies testing denosumab in Prostatic Neoplasms is open now. The open studies under Prostatic Neoplasms, anywhere →

About denosumab

Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,233 Prostatic Neoplasms studies recruiting now, 931 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 10 studies testing denosumab in Prostatic Neoplasms as a file.
02

Study summary

This study will evaluate AMG 162 in the treatment of bone loss in subjects undergoing Androgen-Deprivation Therapy for Non-metastatic Prostate Cancer.

03

Conditions studied

  • Prostate Cancer

Browse trials for

Keywords

  • Prostate Cancer
  • Bone Loss with Prostate Cancer
  • Treatment of bone loss in patients undergoing androgen deprivation therapy (ADT) for non-metastatic prostate cancer (PC).
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Eligibility criteria

Other criteria also apply

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,468 participants (actual)

Study arms

  • Experimental
    AMG 162

    Drug: AMG 162

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • 60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

  • DrugPlacebo

    60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30

06

What researchers measure

Primary outcomes

  1. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

    Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

Secondary outcomes

  1. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24

    Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

  2. Total Hip Bone Mineral Density Percent Change From Baseline at Month 24

    Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 24 months

  3. Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36

    Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 36 months

  4. Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36

    Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 36 months

  5. Total Hip Bone Mineral Density Percent Change From Baseline at Month 36

    Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

    Time frame: 36 months

  6. Number of Participants With Any Fracture Through Month 36

    Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.

    Time frame: 36 months

  7. Number of Participants With a New Vertebral Fracture Through Month 36

    New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.

    Time frame: 36 months

  8. Time to First Clinical Fracture Through Month 36

    A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.

    Time frame: 36 months

  9. Number of Participants With Any Fracture Through Month 24

    Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.

    Time frame: 24 months

07

Results

Posted Jun 3, 2014

Participant flow

First Subject Enrolled: 15-Apr-2004 Last Subject Enrolled: 29-Apr-2005

Participant flow — Overall Study
MilestonePlaceboDenosumab 60 mg Q6M
Started734734
Received study drug730726
Completed445467
Not completed289267
Withdrew: Physician decision42
Withdrew: Adverse event2329
Withdrew: Withdrawal by subject143127
Withdrew: Death4343
Withdrew: Disease progression2123
Withdrew: Ineligibility determined810
Withdrew: Lost to follow-up2117
Withdrew: Noncompliance73
Withdrew: Other59
Withdrew: Requirement for alternative therapy144

Outcome measures

PrimaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24

Lumbar Spine Bone Mineral Density Percent Chnage From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 24-1 (-1.4 to -0.7)5.6 (5.3 to 5.9)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 · Mean difference (final values): 6.7 · 95% CI 6.2 to 7.1
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 24

Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 24-1.5 (-1.8 to -1.1)2.4 (2.1 to 2.8)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Mean difference (final values): 3.9 · 95% CI 3.5 to 4.4
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 24

Total Hip Bone Mineral Density Percent Change From Baseline at Month 24 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
24 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Total Hip Bone Mineral Density Percent Change From Baseline at Month 24-2 (-2.3 to -1.8)2.7 (2.5 to 3.0)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Mean difference (final values): 4.8 · 95% CI 4.4 to 5.1
SecondaryLumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36

Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
36 months
Reported as:
Least squares mean · Percent Change from Baseline
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Lumbar Spine Bone Mineral Density Percent Change From Baseline at Month 36-1.2 (-1.5 to -0.8)6.8 (6.4 to 7.1)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Mean difference (final values): 7.9 · 95% CI 7.4 to 8.4
SecondaryFemoral Neck Bone Mineral Density Percent Change From Baseline at Month 36

Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
36 months
Reported as:
Least squares mean · Percent Change from Baseline
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Femoral Neck Bone Mineral Density Percent Change From Baseline at Month 36-1.8 (-2.2 to -1.5)3 (2.7 to 3.4)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Mean difference (final values): 4.9 · 95% CI 4.4 to 5.4
SecondaryTotal Hip Bone Mineral Density Percent Change From Baseline at Month 36

Total Hip Bone Mineral Density Percent Change From Baseline at Month 36 Assessed by Dual Energy X-Ray Absorptiometry.

Time frame:
36 months
Reported as:
Least squares mean · Percent Change from Baseline
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36
Percent Change from BaselinePlaceboDenosumab 60 mg Q6M
Total Hip Bone Mineral Density Percent Change From Baseline at Month 36-2.6 (-2.8 to -2.3)3.2 (2.9 to 3.4)
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · ANCOVA · p = <0.0001 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Mean difference (final values): 5.7 · 95% CI 5.4 to 6.1
SecondaryNumber of Participants With Any Fracture Through Month 36

Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.

Time frame:
36 months
Reported as:
Number · Participants
Number of Participants With Any Fracture Through Month 36
ParticipantsPlaceboDenosumab 60 mg Q6M
Number of Participants With Any Fracture Through Month 365338
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · Regression, Logistic · p = 0.1048 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Odds ratio (or): 0.7 · 95% CI 0.46 to 1.08
SecondaryNumber of Participants With a New Vertebral Fracture Through Month 36

New Vertebral Fracture Assessed by Lateral Spine X-ray using Genant Semiquantitative Scoring Method excluding any symptomatic new vertebral fracture associated with high trauma severity or a pathologic fracture.

Time frame:
36 months
Reported as:
Number · Participants
Number of Participants With a New Vertebral Fracture Through Month 36
ParticipantsPlaceboDenosumab 60 mg Q6M
Number of Participants With a New Vertebral Fracture Through Month 362610
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · Regression, Logistic · p = 0.0125 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Odds ratio (or): 0.37 · 95% CI 0.18 to 0.78
SecondaryTime to First Clinical Fracture Through Month 36

A clinical fracture was defined as any nonvertebral fracture or clinically evident fracture at the cervical vertebrae, thoracic vertebrae, and lumbar vertebrae that was associated with signs and/or symptoms indicative of a fracture. Fractures associated with high trauma severity and pathologic (ie, metastatic) fractures were excluded. Since the median time was not reached, time to first clinical fracture is represented by the Kaplan-Meier estimate of the percentage of participants with a clinical fracture.

Time frame:
36 months
Reported as:
Number · Percentage of participants
Time to First Clinical Fracture Through Month 36
Percentage of participantsPlaceboDenosumab 60 mg Q6M
Time to First Clinical Fracture Through Month 365.24.7
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · Regression, Cox · p = 0.7961 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Hazard ratio (hr): 0.94 · 95% CI 0.57 to 1.55
SecondaryNumber of Participants With Any Fracture Through Month 24

Any fracture includes osteroporotic fractures at any site excluding skull, facial, mandible, metacarpals, finger phalanges, and toe phalanges.

Time frame:
24 months
Reported as:
Number · Participants
Number of Participants With Any Fracture Through Month 24
ParticipantsPlaceboDenosumab 60 mg Q6M
Number of Participants With Any Fracture Through Month 244532
Statistical analysis
  • Placebo vs Denosumab 60 mg Q6M · Regression, Logistic · p = 0.7961 (Adjusted for multiplicity using the prespecified hierarchical analysis strategy and Hochberg procedure) · Odds ratio (or): 0.7 · 95% CI 0.44 to 1.11

Adverse events

Collected over 36 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—222/725 (30.6%)364/725 (50.2%)
Denosumab 60 mg Q6M—253/731 (34.6%)390/731 (53.4%)
Most frequent serious events
Showing 10 of 382
Most frequent serious events
EventPlaceboDenosumab 60 mg Q6M
Myocardial infarctionCardiac disorders18/72514/731
Cerebrovascular accidentNervous system disorders12/72510/731
Coronary artery diseaseCardiac disorders11/7259/731
PneumoniaInfections and infestations11/72511/731
Atrial fibrillationCardiac disorders8/72511/731
Cardiac failure congestiveCardiac disorders10/7256/731
Metastases to boneNeoplasms benign, malignant and unspecified (incl cysts and polyps)10/7253/731
Transient ischaemic attackNervous system disorders4/7259/731
SyncopeNervous system disorders5/7258/731
DyspnoeaRespiratory, thoracic and mediastinal disorders3/7258/731
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPlaceboDenosumab 60 mg Q6M
ArthralgiaMusculoskeletal and connective tissue disorders79/72591/731
Back painMusculoskeletal and connective tissue disorders73/72579/731
ConstipationGastrointestinal disorders74/72573/731
Pain in extremityMusculoskeletal and connective tissue disorders51/72566/731
HypertensionVascular disorders47/72554/731
Oedema peripheralGeneral disorders47/72552/731
NasopharyngitisInfections and infestations45/72547/731
FatigueGeneral disorders45/72544/731
DizzinessNervous system disorders31/72541/731
Musculoskeletal painMusculoskeletal and connective tissue disorders26/72540/731

Baseline characteristics

Age, Continuous
Age, Continuous(Years)PlaceboDenosumab 60 mg Q6MTotal
Mean75.5 ± 7.175.3 ± 775.4 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboDenosumab 60 mg Q6MTotal
Female000
Male7347341468
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)PlaceboDenosumab 60 mg Q6MTotal
Asian358
Japanese415
American Indian or Alaska Native202
Other303
White or Caucasian6096151224
Black or African American323668
Hispanic or Latino8177158
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Egerdie RB, Saad F, Smith MR, Tammela TL, Heracek J, Sieber P, Ke C, Leder B, Dansey R, Goessl C. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. Prostate Cancer Prostatic Dis. 2012 Sep;15(3):308-12. doi: 10.1038/pcan.2012.18. PubMed 22641239 ↗
  • Lippuner k, Wolff JM, Hadji P, Braun A, Ke C, Steinle T, Eisen C. Risk reduction for vertebral fractures in patients with normal to osteopenic bone mineral density receiving denosumab: A subgroup analysis of the HALT Prostate Cancer Trial. Osteologie 2014;23(2):117-122. [published in German only]
  • Smith MR, Egerdie B, Hernandez Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; Denosumab HALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11. PubMed 19671656 ↗
  • Smith MR, Saad F, Egerdie B, Sieber P, Tammela TLj, Leder BZ, Ke C, Goessl C. Denosumab and changes in bone turnover markers during androgen deprivation therapy for prostate cancer. J Bone Miner Res. 2011 Dec;26(12):2827-33. doi: 10.1002/jbmr.492. PubMed 21898590 ↗
  • Smith MR, Saad F, Egerdie B, Szwedowski M, Tammela TL, Ke C, Leder BZ, Goessl C. Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol. 2009 Dec;182(6):2670-5. doi: 10.1016/j.juro.2009.08.048. PubMed 19836774 ↗
  • Kuchler U, Luvizuto ER, Tangl S, Watzek G, Gruber R. Short-term teriparatide delivery and osseointegration: a clinical feasibility study. J Dent Res. 2011 Aug;90(8):1001-6. doi: 10.1177/0022034511407920. Epub 2011 May 9. PubMed 21555773 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2004 to primary completion in May 2008, 45 months.

Results were first posted in Jun 2014, 6 years after primary completion. A results delay was requested in Nov 2009.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 45 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 9, 2004
First posted
Aug 11, 2004
StartActual
Aug 1, 2004
Primary completionActual
May 16, 2008
CompletionActual
May 11, 2010
Results delay requested
Nov 23, 2009
Results first posted
Jun 3, 2014
Last update
Oct 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00089674
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Aug 11, 2004
Start date
Aug 1, 2004
Primary completion
May 16, 2008
Completion
May 11, 2010
Results posted
Jun 3, 2014
Last update
Oct 17, 2018

Study contacts

MD
study director · Amgen
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Denosumab

Start the discussion